NOVN.SW

$115.60-1.28 (-1.10%)

Market ClosedAs of Mar 20, 4:30 PM UTC

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$115.60
Potential Upside
18.3%
Whystock Fair Value$136.75
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - General

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart f...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$220.58B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.42
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Strong income play. Yield provides a meaningful total return floor.
320.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
30.81%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.82

Recent News

The Wall Street Journal
Mar 20, 2026

Health Care Roundup: Market Talk

Find insight on Novartis, Chulurat Hospital and more in the latest Market Talks covering Health Care.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
The Wall Street Journal
Mar 20, 2026

Stocks to Watch Recap: Super Micro Computer, FedEx, Unilever

↗️ FedEx (FDX): The shipping company raised its outlook as revenue increased in the fiscal third quarter. Shares rose 0.8%. ↘️ Super Micro Computer (SMCI): The technology company placed two employees on leave and fired a contractor after learning of their alleged involvement in a scheme to divert computer servers assembled in the U.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 20, 2026

Novartis Strikes $3B Oncology Deal for Breast Cancer Asset

NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term pipeline growth.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 20, 2026

Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?

BMY's Sotyktu PsA approval boosts its immunology push, expands market reach, and sharpens its competitive stance amid pressure from legacy drug declines.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 20, 2026

Novartis Agrees Up to $3 Billion Synnovation Breast Cancer Drug Deal

Swiss drugmaker commits $2 billion upfront plus milestones to acquire early-stage HR+/HER2- therapy, reinforcing its oncology pipeline.

BEARISH
Negative press. News cycle fixated on risk factors or misses.